Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
Month
1
2
3
4
5
6
7
8
9
10
11
12
07
2021-05
Boan Biotech's 博优诺® Obtains Marketing Authorization in China
06
2021-05
Boan Biotech Obtains Approval for Initiating Clinical Trial for Nivolumab Injection (LY01015) in China
06
2021-05
Boan Biotech’s Neutralizing Antibody against SARS-CoV-2 Completes Phase I Clinical Trial in China, With Good Results in Safety and Tolerance
25
2021-04
Boan Publishes LY-CovMab Research Results in Nature Sub-journal
30
2021-03
Boan Biotech to Present New Preclinical Data for CD3/CEA BsAb at AACR 2021
25
2021-02
Boan Biotech’s Nivolumab Injection LY01015 to Start Clinical Trials in China, As the first applied biosimilar to Opdivo® according to Registration Classification 3.3 of Biological Product
08
2021-02
Boan Biotech Completes First Patient Dosing in Phase Ⅲ Clinical Trial for LY09004, Multiple R&D Projects Under Intensive Development
26
2021-01
Boan Biotech Receives Further Investments with the Total Amount Reaching RMB 877 Million
18
2021-01
Boan Biotech Completes Enrollment of Subjects in Phase I Clinical Trial for Its Neutralizing Antibody Against SARS-CoV-2
05
2021-01
Boan Biotech Receives 682 Million RMB in Strategic Investments, Accelerating Global Development of Its Biopharmaceutical Business
1
2
3
4
5
Follow me
